Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
April 2018
-
Media ReleaseNovartis delivered a strong first quarter and acted to become a more focused medicines companyNet sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong…
-
Media ReleaseSandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disordersDeal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
-
Media ReleaseNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failuresThe LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials …
-
Media ReleaseNovartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarialsCompany to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
-
Key ReleaseNovartis tender offer for AveXis commencesBasel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
-
Media ReleaseNovartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetesHeart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
-
Key ReleaseNovartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leaderAveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong…
-
Media ReleaseSandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovationSandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World…
-
Media ReleaseNovartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalaprilPost-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
March 2018
-
Media ReleaseNovartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVOBasel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
-
Media ReleaseAveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Key ReleaseNovartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic prioritiesPrice reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
Pagination
- ‹ Previous page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- …
- 88
- › Next page